Compumedics Ltd to announces the confirmation of its first magnetoencephalography (MEG) contract to Barrow Neurological Institute (BNI) in Phoenix, Ariz.
The contract establishes a strong collaboration with BNI including American Food and Drug Administration applications and beta-site services such as biomarker test protocols and access to secure patient databases for epilepsy, autism, dementia, and Parkinson’s disease management services, along with associated clinical validation and verification studies. Additionally, later collaborative stages will include working on improved and expanded CPT/IDT (government health reimbursement) codes to help enhance brain healthcare.
David Burton, PhD, Executive Chairman of Compumedics, says in a release: “We are very pleased and honored to announce this strategic BNI MEG milestone, representing the largest system contract in Compumedics’ history. In 2016 Compumedics Neuroscan and KRISS united their achievements and ongoing efforts, as part of a comprehensive 20-year exclusive Technology Transfer and License Agreement, to produce the new Orion LifeSpan MEG. After almost a year of extraordinary scrutiny by some of the world’s most distinguished neurosurgeons, neuroscientists, and clinical experts at BNI, Compumedics Neuroscan, KRISS, and BNI are inspired and intensely focused more than ever on our shared mission to transform brain health.”
MEG is a functional neuroimaging technique for mapping brain activity by recording magnetic fields produced by electrical currents occurring naturally in the brain, using very sensitive magnetometers. Compumedics has overcome earlier MEG system barriers with Orion LifeSpan’s increased precision coupled with fully-integrated MEG (Curry MEG) brain analysis software.
